Skip to content
Screener
Denali Therapeutics Inc. logo

Denali Therapeutics Inc.

DNLI

Denali Therapeutics is a clinical-stage biotechnology company focused on developing a broad portfolio of biotherapeutics for neurodegenerative and lysosomal storage diseases.

Market cap
$3.21B+67.9%
Revenue$3.6M+184%
Net income-$511.5M-6.8%
Free cash flow-$437.5M-18.9%
EPS (diluted)-$2.84-1.1%
Trailing twelve months · change vs. prior year

Earnings

Q2 2026 report

August 6, 2026
Revenue$3.6MBeat by $1.4MEPS-$0.68Miss by $0.17

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$12.2M
EPS estimate-$0.37

Financials

Q2 2026

Income statement

See full
Revenue$3.6M—
Gross profit$3.5M—
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation & ratios

Valuation

See full
Market cap$3.21B+67.9%
Enterprise value$3.04B+67.6%
P/S889.7×—

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0×0.0×
Current ratio8.4×-1.9×

Segments

By product

See full
Milestone Triggered$25.0M0.0%
Milestone Payment$2.5M0.0%
Option Fee Payment$2.5M+100%

Competitors

By market cap

Eli Lilly logo
Eli Lilly$1.01T+48.8%
Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals$79.7B+28.5%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.$3.2B+67.9%
uniQure logo
uniQure$2.9B+279%
Ultragenyx Pharmaceutical logo
Ultragenyx Pharmaceutical$1.3B-54.1%
Alector, Inc. logo
Alector, Inc.$214.9M-28.0%
Atrium Therapeutics logo
Atrium Therapeutics$162.5M-97.2%
PAS
Passage Bio, Inc.$15.6M-30.0%

By revenue growth

Denali Therapeutics Inc. logo
Denali Therapeutics Inc.+184%
Eli Lilly logo
Eli Lilly+49.6%
uniQure logo
uniQure+30.2%
Ultragenyx Pharmaceutical logo
Ultragenyx Pharmaceutical+17.5%
Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals+9.3%

By net margin

Eli Lilly logo
Eli Lilly33.53%+7.6pp
Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals27.86%-3.5pp
Ultragenyx Pharmaceutical logo
Ultragenyx Pharmaceutical-81.7%+5.6pp
uniQure logo
uniQure-1,350.73%+37.3pp
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.-33,121.86%+23,617pp

Profile

Denali Therapeutics is a clinical-stage biotechnology company focused on developing a broad portfolio of biotherapeutics for neurodegenerative and lysosomal storage diseases. The company leverages its proprietary Transport Vehicle (TV) technology platform to engineer large molecules, such as enzymes and antibodies, that can effectively cross the blood-brain barrier. Their core value proposition lies in transforming the treatment of central nervous system disorders by enabling systemic delivery of brain-penetrant medicines.

Competitive position

A leader in blood-brain barrier delivery technology with a proprietary platform that enables a modular approach to treating diverse CNS and systemic diseases.

GeographiesUnited States, European Union, China, Switzerland
Customer segmentsRare disease patients, Neurodegenerative disease patients, Pharmaceutical companies
Business modelR&D intensive, Licensing and Royalties, Collaborative Development
SuppliersContract Development and Manufacturing Organizations (CDMOs), Academic research institutions, Specialized laboratory equipment suppliers, Clinical trial site operators
CustomersSpecialty pharmacies, Hospitals and infusion centers, Biopharmaceutical collaboration partners, Government and private healthcare payers
CountryUnited States of America
Listed2017
Employees375.0
CEORyan J. Watts
SectorHealthcare
IndustryBiotechnology
Websitedenalitherapeutics.com
FilingsSEC EDGAR

FAQ

What is Denali Therapeutics Inc.'s market cap?
Denali Therapeutics Inc. (DNLI) has a market capitalization of $3.2B and trades on NASDAQ.
What is Denali Therapeutics Inc.'s revenue and profitability?
Denali Therapeutics Inc. generated $3.6M in trailing twelve-month revenue with a net loss of $511.5M, representing a net margin of -33121.9%, with free cash flow of -$437.5M. The latest reported period is Q2 2026.
Who are Denali Therapeutics Inc.'s competitors?
Denali Therapeutics Inc.'s key competitors include Alector, Inc., Eli Lilly and Company, Ultragenyx Pharmaceutical Inc., and others. These companies compete in similar markets and product categories.
Who does Denali Therapeutics Inc. partner with?
Denali Therapeutics Inc.'s notable partners include Biogen Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., and others.
What subsidiaries does Denali Therapeutics Inc. have?
Denali Therapeutics Inc.'s subsidiaries include Denali BBB Holding Limited.
Where is Denali Therapeutics Inc. headquartered?
Denali Therapeutics Inc. is headquartered in United States of America and employs approximately 375 people. It has been publicly traded since 2017.